問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Surgery

Division of General Internal Medicine

Division of Hematology & Oncology

Digestive System Department

更新時間：2023-09-19

賴學洲Lai, Hsueh-Chou
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • D3145@mail.cmuh.org.tw

Recruiting Trial

45Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

賴學洲

List

124Cases

2007-03-01 - 2008-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

2017-02-01 - 2019-06-30

Others

A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects

  • Condition/Disease

    The plan includes adult male and female CHB subjects aged 18 to 70 (inclusive) who are not currently receiving CHB treatment. Part 1 (Groups A, B, C, and D) will include HBeAg-positive subjects, while Part 1 (Group C1) will include HBeAg-negative subjects. After completing part 1 of the administration (after reviewing the safety, tolerability, PK and PD differences between HBeAg status), the specific CHB group included in part 2 will be determined

  • Test Drug

    GSK3389404

Participate Sites
9Sites

Recruiting8Sites

2016-02-01 - 2019-05-01

Phase III

A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Nivolumab/Sorafenib

Participate Sites
8Sites

Terminated7Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

彭成元
China Medical University Hospital-Taipei

未分科

2016-09-01 - 2018-11-30

Others

A Phase 1/2, Randomized, Single-Blind, Placebo-Controlled, Single-Ascending and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Antiviral Efficacy Study of Subcutaneously Administered ALN-HBV in Healthy Adult Subjects and Non-cirrhotic Patients with Chronic Hepatitis B Virus (HBV) Infection

  • Condition/Disease

    Chronic Hepatitis B Virus (HBV) Infection

  • Test Drug

    ALN-HBV

Participate Sites
6Sites

Terminated5Sites

2020-12-02 - 2022-07-26

Phase II

Phase llb Multi=Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy a and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis Z Virus(B-Clear)nd Safety

  • Condition/Disease

    Patients with chronic hepatitis B virus

  • Test Drug

    GSK3228836

Participate Sites
4Sites

Recruiting4Sites

2017-03-03 - 2023-02-28

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

  • Condition/Disease

    Nonalcoholic Steatohepatitis(NASH)

  • Test Drug

    Selonsertib

Participate Sites
20Sites

Terminated18Sites

黃志富
Kaohsiung Municipal Gangshan Hospital

未分科

沈一嫻
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2015-11-01 - 2018-03-31

Phase III

A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 weeks in Subjects with Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection

  • Condition/Disease

    Antiviral efficacy of chronic infection with hepatitis C virus (HCV) of genotype 1 or 2

  • Test Drug

    Harvoni®

Participate Sites
15Sites

Terminated14Sites

彭成元
China Medical University Hospital-Taipei

未分科

朱啟仁
Taipei Veterans General Hospital

2018-11-01 - 2025-12-31

Phase III

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)

  • Condition/Disease

    advanced stage hepatocellular carcinoma

  • Test Drug

    Keytruda® / Lenvima®

Participate Sites
9Sites

Terminated7Sites

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2014-06-01 - 2016-04-30

Phase III

A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    MK-5172A

Participate Sites
3Sites

Terminated3Sites

1 6 7 8 9 10 13
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB